Victor Gonzalez-Uribe

Dr. Victor Gonzalez-Uribe

Facultad Mexicana de Medicina, Universidad La Salle, Mexico City, Ciudad de México, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
STSergio de Jesus Romero Tapia
Sergio de Jesus Romero Tapia
CRCarlos E. Rodriguez-Martinez
Carlos E. Rodriguez-Martinez
Asthma is a widespread disease affecting approximately 300-million people globally. This condition leads to significant morbidity, mortality, and economic strain worldwide. Recent clinical and laboratory research advancements have illuminated the immunological factors contributing to asthma. As of now, asthma is understood to be a heterogeneous disease. Personalized medicine involves categorizing asthma by its endotypes, linking observable characteristics to specific immunological mechanisms. Identifying these endotypic mechanisms is paramount in accurately profiling patients and tailoring therapeutic approaches using innovative biological agents targeting distinct immune pathways. This article presents a synopsis of the key immunological mechanisms implicated in the pathogenesis and manifestation of the disease’s phenotypic traits and individualized treatments for severe asthma subtypes.

1 January 2023 in Asian Pacific Journal of Allergy and Immunology
Verified
Journal Article
Closed access
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
HCHelena Vidaurri-De la Cruz
Helena Vidaurri-De la Cruz
AGAndres Gomez-Nuñez
Andres Gomez-Nuñez
JLJordi A Leyva-Calderon
Jordi A Leyva-Calderon
ZMZaira S Mojica-Gonzalez
Zaira S Mojica-Gonzalez
Atopic dermatitis is associated with an increased frequency of other atopic & allergic manifestations, including asthma in 10% to 30% of cases depending on age, allergic rhinitis, food allergies, eosinophilic diseases, and allergic conjunctivitis. The comorbidities outside the atopic march are overall less frequent than in psoriasis. This review aims to demonstrate the intense, broad burden of this disease, comorbidities and its multidimensional involvement as a complex, heterogeneous disease. Methods: The present narrative review summarizes the findings from the world's largest epidemiological studies and smaller, AD-specific studies on the comorbidities and burdens of this disease. Results: The risk of asthma, specifically, and other atopic manifestations and skin infections, generally, is clearly increased among patients with AD. Of the other skin diseases, there is an undeniable risk of alopecia areata, vitiligo, and contact eczema and a lower risk of developing other autoimmune diseases. While comorbidities exist, their frequency seems to be modified by lifestyle, particularly by smoking. There is a link with overweight, obesity, and metabolic syndrome, especially in severe AD. This is also the case for cardiovascular diseases; however, with OR/HRs below 1.5. There is no link to type II diabetes but, rather, to type I in children. In all other areas, the data are often inconsistent, and any increase in risk is low. Eye diseases seem to be the only exception. AD also has psychiatric consequences, including attention-hyperactivity disorder, anxiety, depression, and sometimes suicidality, especially when severe. Conclusions: The recently published work largely confirms our existing understanding of AD.

1 August 2024 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
BMBlanca María Morfín-Maciel
Blanca María Morfín-Maciel
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
CGClaudia Ivonne Gallego-Corella
Claudia Ivonne Gallego-Corella
GRGermán Agustín Rico-Solís
Germán Agustín Rico-Solís
MEMaría del Carmen Calderón Ezquerro
María del Carmen Calderón Ezquerro
Introduction: Aeroallergen exposure has an intra- and extra-domiciliary component and varies according to climatological zones. Mexico is a large country with a great variety of climates. A previous study (2009) evaluated skin prick test results (SPT) in different regions. In this study, we compare previous sensitization patterns from 14y ago with current ones and compare them between different climatological zones. Methods: Mexican allergists were asked to share their last 100 SPT results in patients with respiratory allergy. Clinics were grouped in (semi)humid vs (semi)dry zones. Results were analyzed nationwide and compared to the 2009 results, calculating odds ratio (OR) and 95% confidence intervals (95% CIs), with p < 0.05 as cut-off. Similarly, we compared (semi)humid versus dry zones. Results: We collected 2915 SPT results from 28 clinics (19 cities). Dermatophagoides was the most frequently sensitizing allergen. There was a significant increase in SPT positivity from 2009 to 2023 in both in- and outdoor aeroallergens (OR 1.26– 2.65, 95% CI from 1.06– 1.50 to 1.99– 3.52). Comparing dry-humid zones, sensitization to pollen from Oleaceae, Fagaceae (p < 0.0001 all) and most weeds is more frequent in humid zones, as are Dermatophagoides and cockroach (both p < 0.0001). Eucalyptus, mesquite, and all grass pollen sensitizations predominate in dry zones (p < 0.05– 0.0001). There are no differences in sensitization to cat or dog between zones. Conclusion: We found a general increase in SPT sensitization over the past fourteen years, suggesting that this is probably not only due to climate change. The different sensitization profile throughout the country was mainly related to humidity. Repeating epidemiologic SPT studies over the years could help tracking changes in allergen sensitization over time.

1 January 2022 in Medical Research Archives
Verified
Journal Article
Closed access
PDF file
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
RMRicardo Martinez-Tenopala
Ricardo Martinez-Tenopala
PBPaola Baro-Alvarez
Paola Baro-Alvarez
ZMZaira Mojica-Gonzalez
Zaira Mojica-Gonzalez
Background: Asthma is a chronic allergic disease characterized by variable airflow limitation; Obesity is a chronic disease that has reached epidemic proportions globally. Both are diseases with a significant inflammatory component, and their relationship suggests being weight dependent. Adiponectin (ADIPOQ) is the main adipokine secreted by white adipose tissue, it is an insulin synthesizer and regulator of energy homeostasis, and its plasma levels are inversely correlated with obesity and asthma. The effect of genetic factors in both diseases has been investigated, and haplotypes of the ADIPOQ 45 T/G (rs2241766) and ADIPOQ 276 G/T (rs1501299) polymorphisms have been related. Aims: To know de polymorphisms frequency of ADIPOQ 45 and ADIPO 276 in obese and eutrophic adolescents with and without asthma, likewise, link the adiponectin levels with the presence of such polymorphisms. Methods: An observational, analytical, and cross-sectional study in which 169 Mexican adolescents were recruited. Thirty mL of blood was taken from each individual; genomic DNA was extracted using the saline expulsion technique and quantified by spectrophotometry; two polymorphisms located in the promoter region were studied: ADIPOQ 45 and ADIPOQ 276; the determination of the different polymorphisms was carried out using TaqMan probes using real-time PCR (qPCR) using the commercial kit TaqMan One Step RT-PCR mastermix, the RNA extraction was carried out with Trizol Ls (Invitrogen), and the fluorescence was quantified employing the 7900HT ABI PRISM real-time computer SDS software. Results: There were no statistically significant differences between ADIPOQ 276 and ADIPOQ 45 polymorphisms in asthmatic and obese patients. Compared to the control group, a negative correlation was observed between adiponectin plasmatic levels in obese and asthmatic individuals. Conclusion: The ADIPOQ 276 and ADIPOQ 45 polymorphisms do not seem to be associated with asthma and obesity in the Mexican population. It is necessary to continue studying these polymorphisms and consider larger populations.

24 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
STSergio de Jesus Romero Tapia
Sergio de Jesus Romero Tapia
CRCarlos E. Rodriguez-Martinez
Carlos E. Rodriguez-Martinez
Asthma is a prevalent disease that around 300 million worldwide, resulting in substantial morbidity, mortality, and economic burden on a global scale. New clinical and laboratory research has shed light on the immunology causing asthma. Asthma is now recognized as a heterogeneous disease. A personalized medicine is based on the classification of asthma by endotype by linking observable characteristics to immunological mechanisms. Identifying endotype mechanisms is essential for better characterizing patients and personalizing therapeutic approaches with novel biological agents that target specific immune pathways. This article provides a summary of the major immunological mechanisms involved in the pathogenesis and emergence of the disease's phenotypic features, as well as the individualized treatment for severe asthma subtypes

14 January 2025
Verified
Journal Article
Open access
PDF file
LHLuis Angel Hernández-Zárate
Luis Angel Hernández-Zárate
CGCarlos Andrés Gómez-Núñez
Carlos Andrés Gómez-Núñez
SNStefan Narváez-Labuhn
Stefan Narváez-Labuhn
GMGerardo Morales-Velázquez
Gerardo Morales-Velázquez
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder affecting millions worldwide, with significant variations in clinical presentation influenced by socioeconomic, racial, and environmental factors. This review explores the current understanding of AD pathophysiology, emphasizing immune dysregulation, epithelial barrier dysfunction, and the role of cytokines, particularly interleukin (IL)-4 and IL-13, in disease progression. Safety and efficacy concerns limit traditional corticosteroids, phototherapy, and systemic immunosuppressants, prompting interest in innovative therapies. New biologic agents, including monoclonal antibodies (mAbs) and Janus kinase (JAK) inhibitors (JAKis), target specific immune pathways, promising outcomes in moderate-to-severe AD cases. Biologics like dupilumab and emerging JAKis have shown substantial efficacy and safety in clinical trials, with notable reductions in inflammation and pruritus. However, these advancements present challenges, including hypersensitivity risks and the high costs of biologics, underscoring the need for further research on long-term safety and accessibility. The shift toward precision medicine in AD management marks a significant evolution, with future approaches likely to integrate targeted therapies alongside multidisciplinary care to enhance patient outcomes and quality of life (QoL).